Andrew D. Rhim, M.D.
Instructor A of Medicine
Instructor, Perelman School of Medicine
University of Pennsylvania
Department: Medicine
Contact information
415 Curie Blvd.
655 CRB/ GI
Philadelphia, PA 19104
655 CRB/ GI
Philadelphia, PA 19104
Office: (215) 573-3933
Fax: (215) 573-2024
Lab: (215) 573-1858
Fax: (215) 573-2024
Lab: (215) 573-1858
Email:
arhim@mail.med.upenn.edu
arhim@mail.med.upenn.edu
Education:
B.A. (Biological Basis of Behavior)
University of Pennsylvania, 1999.
M.D. (Medicine)
University of Pennsylvania, 2004.
B.A. (Biological Basis of Behavior)
University of Pennsylvania, 1999.
M.D. (Medicine)
University of Pennsylvania, 2004.
Post-Graduate Training
Internal Medicine, Hospital of the University of Pennsylvania, 2004-2006.
Gastroenterology, Hospital of the University of Pennsylvania, 2006-2010.
Genetics, University of Pennsylvania School of Medicine, Laboratory of Ben Stanger MD, PhD, 2007-2011.
Permanent linkInternal Medicine, Hospital of the University of Pennsylvania, 2004-2006.
Gastroenterology, Hospital of the University of Pennsylvania, 2006-2010.
Genetics, University of Pennsylvania School of Medicine, Laboratory of Ben Stanger MD, PhD, 2007-2011.
Description of Research Expertise
My research program is focused on the biology of pre-cancerous lesions of the pancreas and the early molecular and cellular events that occur during the transition to pancreatic ductal adenocarcinoma (PDAC). The overarching goal of these studies is to learn more about how PDAC evolves so that we may devise new strategies for early diagnosis.Three themes underscore our work: 1) Dissecting the interactions between the pancreatic epithelium and the inflammatory stromal compartment during pancreatitis, precancer (PanIN), and cancer development; 2) Understanding the molecular and cellular requirements, kinetics and geography of blood-borne dissemination and metastasis of pancreas cells; and 3) Analyzing the genetic and genomic changes that drive the development and progression of precancerous lesions of the pancreas.
Our studies employ genetically engineered mouse models of PanIN and PDAC development. We are also engaged in translational studies of our work from the mouse model with human specimens. Clinical studies have been initiated to study potential biomarkers of and therapeutics for pancreatic cancer.
Selected Publications
Rhim AD, Mirek ET, Aiello NA, Maitra A, Bailey JL, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ: EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2): 349-61, January 2012 Notes: Accompanying editorial: Tuveson, D.A. and Neoptolemos, J.P. 2012. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148(1-2):21-3. Comment in: Nature Reviews Cancer, Faculty of 1000, Cancer Research, Cancer Discovery.Bayne LJ, Beatty GL, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH : Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer Cancer Cell 21(6): 822-35, June 2012.
Plentz R, Park JS, Rhim AD, Abravanel D, Hezel A, Sharma SV, Gurumurthy S, Deshpande V, Kenific C, Settleman J, Majumder PK, Stanger BZ, Bardeesy N: Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136(5): 1741-9.e6, May 2009.
Rhim AD: A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu? Cancer biology & therapy 8(20): 1902-3, Oct 2009.
